Group 1 - The core announcement is regarding the positive interim results from the ongoing Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain (CINP) conducted by Dogwood Therapeutics, Inc. [1] - The study involved 97 patients who completed treatment, showing a significant difference in pain improvement between those receiving Halneuron and those on placebo [1]. - The average duration of CINP among the study participants was 5 years, with 67% of patients concurrently on stable doses of other chronic pain medications [2]. Group 2 - The overall dropout rate for the study was approximately 4.4%, which is significantly lower than the dropout rates of other FDA-approved chronic pain medications [2]. - Dogwood anticipates obtaining preliminary results by Q3 2026, based on the current recruitment pace and interim analysis results, with an expected statistical power of 80% to 85% to detect treatment differences [2]. - Dogwood is a development-stage biopharmaceutical company focused on developing new drugs for pain relief and neuropathic symptoms, holding approximately 83% indirect equity interest in Dogwood [2].

Group 1 - The core announcement is regarding the positive interim results from the ongoing Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain (CINP) conducted by Dogwood Therapeutics, Inc. [1] - The study involved 97 patients who completed treatment, showing a significant difference in pain improvement between those receiving Halneuron and those on placebo [1] - Dogwood emphasizes that the preliminary evidence of Halneuron's effectiveness is noteworthy, especially considering that 67% of the patients were concurrently on stable doses of other chronic pain medications [2] Group 2 - The overall dropout rate for the study was approximately 4.4%, which is significantly lower than the dropout rates of other FDA-approved chronic pain medications [2] - Despite being in a blinded phase, Dogwood believes the findings reaffirm the encouraging safety and tolerability observed in previous clinical trials of Halneuron [2] - The company anticipates obtaining preliminary results by Q3 2026, with the current study expected to provide about 80% to 85% statistical power to detect treatment differences [2] Group 3 - Dogwood Therapeutics is a development-stage biopharmaceutical company registered in Delaware and listed on the NASDAQ under the ticker DWTX, focusing on developing new drugs for alleviating pain and neurological discomfort [2] - The company currently holds approximately 83% indirect equity interest in Dogwood [2]

Core Insights - Changjiang Life Sciences Technology (00775.HK) announced the latest developments regarding its investment in Dogwood Therapeutics, Inc. (DWTX), a biopharmaceutical company focused on developing new drugs for pain relief and neuropathic symptoms, holding approximately 83% indirect equity in Dogwood [1] Group 1: Clinical Trial Results - Dogwood reported positive mid-term analysis results from its ongoing Phase 2b study of Halneuron® for chemotherapy-induced neuropathic pain (CINP), with 97 patients completing treatment [1] - The independent statistical review committee found a significant difference in pain improvement between patients treated with Halneuron® and those receiving a placebo during the four-week study [1] Group 2: Patient Demographics and Treatment Context - The average duration of CINP among patients in the mid-term analysis was 5 years, with 67% of eligible patients concurrently receiving stable doses of other chronic pain medications, including pregabalin, gabapentin, duloxetine, and opioids [2] - The overall dropout rate for the study was approximately 4.4%, significantly lower than the dropout rates of other FDA-approved chronic pain medications [2] Group 3: Future Expectations - Dogwood anticipates obtaining preliminary results from the Phase 2b trial by the third quarter of 2026, based on current recruitment speed and mid-term evaluation results [2] - The ongoing study is expected to provide approximately 80% to 85% statistical power to detect treatment differences for Halneuron® [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 Dogwood 表示Halneuron® 治療效果的初步證據值得關注，基於中期分析群組中患者平均 CINP 患期為 5 年，且 67% 符合入組標準的患者同時接受其他慢性疼痛藥物的穩定劑量治 療，包括普瑞巴林（pregabalin）、加巴噴丁（gabapentin）、度洛西汀（duloxetine）及 類鴉片（opioids）藥物。此外，該研究的整體退出率約4.4%，遠低於其他美國食品及 藥物管理局批准的慢性疼痛藥物的退出率。儘管目前仍處於盲法階段，惟 Dogwood認為 是項發現再次證明 Halneuron® 在先前臨床試驗中觀察所得令人鼓舞的安全性及耐受性。 根據目前第二b 期試驗的招募速度及中期評估結果，Dogwood 仍預計將在二零二六年第三 季內獲得初步結果。目前的研究預計將提供約 80% 至 85% 的統計功效以檢測Halneuron® 的治療差異。 務請注意，Halneuron® 目前仍處 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：0775） 持續關連交易 提供管理服務 預 期 現 有 管 理 協 議 將 於 二 零 二 五 年 十 二 月 三 十 一 日 屆 滿 ， 於 二 零 二 五 年 十 二 月 十 九 日 （交易時段後），本公司全資附屬公司RMSPL與長江實業全資附屬公司 IPL訂立新管理 協議，內容有關委任RMSPL作為管理人並於二零二六年一月一日起至二零二八年十二月 三十一日止期間就許可地區內的物業向IPL提供服務。 鑑於李嘉誠先生、董事李澤鉅先生及信託被聯交所視作一組關連人士，故根據上市規則， 長江實業可能被視為本公司的關連人士。根據上市規則，長江實業全資附屬公司IPL亦可能 被 視 為 本 公 司 的 關 連 人 士 ， 故 RMSPL 與 IPL 訂 立 新 管 理 協 議 構 成 本 公 司 於 上 市 規 則 第14A章項下的持續關連交易。 由於就新管理協議項下 ...

致：香港交易及結算所有限公司 公司名稱: 長江生命科技集團有限公司 呈交日期: 2025年12月2日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00775 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 15,000,000,000 | | HKD | | 0.1 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | 本月底法定/註冊股本 ...

Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas listing applications, including a request for Huanchuang Technology to clarify the reasonableness of the share price for new shareholders in the last 12 months [1] - Huanchuang Technology has submitted a listing application to the Hong Kong Stock Exchange, with CICC and Guosen Securities (Hong Kong) as joint sponsors [1] - The CSRC has requested legal opinions on several matters, including the fairness of the share price for the equity incentive plan and the operational status of the advertising business [1][2] Group 2 - Huanchuang Technology is a leading global provider of high-precision spatial perception solutions, utilizing AI technology to build intelligent spatial perception systems for smart robots [2] - According to Frost & Sullivan, Huanchuang Technology is a market leader in the laser radar product segment for robotic vacuum cleaners, with a shipment volume of approximately 8 million units in 2024, capturing over 50% of the market share by shipment volume [2] - The company has achieved a cumulative shipment volume of over 25 million units since its establishment and continues to show steady growth in the first half of 2025, with total shipments of laser radar and line laser sensors exceeding 5 million and 2 million units, respectively [2]

Core Viewpoint - Changjiang Life Science Technology (00775) has seen a significant increase of over 8%, currently trading at 1.01 HKD, with a transaction volume of 23.28 million HKD, following the presentation of its cancer immunotherapy research results at the SITC 2025 conference [1] Group 1 - The company showcased major advancements in cancer vaccine development targeting TROP2, PRAME, and PD-L1, highlighting their potential to inhibit tumor growth [1] - Dr. Du Jianming, Vice President and Chief Scientific Officer of the company, expressed optimism about the results of the cancer vaccine candidates targeting TROP2 and PRAME/PD-L1, indicating that these developments could accelerate the progress of effective therapeutic cancer vaccines [1] - The current goal of the company is to advance these vaccine candidates to the clinical trial stage [1]

Core Viewpoint - Changjiang Life Science Technology (00775.HK) has seen a significant increase in its stock price, rising over 8% to HKD 1.01, with a trading volume of HKD 23.28 million [2] Group 1 - The stock price of Changjiang Life Science Technology increased by 8.6% [2] - The current trading price is reported at HKD 1.01 [2] - The total trading volume reached HKD 23.28 million [2]

Core Viewpoint - Changjiang Life Sciences (00775) saw a significant stock increase of 8.6%, reaching HKD 1.01, with a trading volume of HKD 23.28 million, following the presentation of its cancer immunotherapy research at the SITC 2025 conference [1] Group 1: Company Developments - Changjiang Life Sciences showcased its research advancements in cancer vaccines targeting TROP2, PRAME, and PD-L1 at the SITC 2025 conference [1] - The company’s Vice President and Chief Scientific Officer, Dr. Du Jianming, expressed optimism about the progress of the cancer vaccine candidates targeting TROP2 and PRAME/PD-L1, indicating a potential acceleration in the development of effective therapeutic cancer vaccines [1] - The current objective for the company is to advance these vaccine candidates to the clinical trial stage [1]